Calquence
Chemical Name | acalabrutinib |
Dosage Form | Capsule (oral; 100 mg) |
Drug Class | Kinase inhibitors |
System | Blood |
Company | AstraZeneca |
Approval Year | 2017 |
Indication
- Calquence is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Calquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).